XBiotech Historical Balance Sheet
XBIT Stock | USD 7.35 0.54 7.93% |
Trend analysis of XBiotech balance sheet accounts such as Total Assets of 209.4 M, Short Long Term Debt Total of 800, Other Current Liabilities of 6.5 M or Total Current Liabilities of 9.4 M provides information on XBiotech's total assets, liabilities, and equity, which is the actual value of XBiotech to its prevalent stockholders. By breaking down trends over time using XBiotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining XBiotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XBiotech is a good buy for the upcoming year.
XBiotech Inventory |
|
XBiotech |
About XBiotech Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of XBiotech at a specified time, usually calculated after every quarter, six months, or one year. XBiotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of XBiotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which XBiotech currently owns. An asset can also be divided into two categories, current and non-current.
XBiotech Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of XBiotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in XBiotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Long Term Debt
Long-term debt is a debt that XBiotech has held for over one year. Long-term debt appears on XBiotech balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on XBiotech balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most accounts from XBiotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into XBiotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XBiotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.At this time, XBiotech's Other Current Liabilities is comparatively stable compared to the past year. Total Current Liabilities is likely to gain to about 9.4 M in 2024, whereas Property Plant And Equipment Net is likely to drop slightly above 22.6 M in 2024.
2023 | 2024 (projected) | Short and Long Term Debt Total | 900.0 | 800.0 | Total Assets | 226.6M | 209.4M |
XBiotech balance sheet Correlations
Click cells to compare fundamentals
XBiotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
XBiotech balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 816.9M | 353.7M | 275.2M | 246.1M | 226.6M | 209.4M | |
Other Current Liab | 53.5M | 1.4M | 1.4M | 1.6M | 3.5M | 6.5M | |
Total Current Liabilities | 60.2M | 4.0M | 3.5M | 4.1M | 6.1M | 9.4M | |
Total Stockholder Equity | 755.6M | 348.6M | 269.4M | 240.4M | 218.8M | 199.2M | |
Property Plant And Equipment Net | 25.2M | 27.3M | 28.3M | 26.3M | 24.9M | 22.6M | |
Net Debt | (714.6M) | (237.4M) | (237.0M) | (157.3M) | (200.0M) | (210.0M) | |
Retained Earnings | 430.9M | 97.6M | 5.2M | (27.7M) | (52.3M) | (54.9M) | |
Accounts Payable | 2.1M | 2.5M | 2.1M | 2.4M | 2.5M | 2.5M | |
Cash | 714.6M | 237.4M | 237.0M | 157.3M | 200.0M | 163.9M | |
Non Current Assets Total | 100.6M | 27.9M | 28.3M | 26.3M | 24.9M | 29.6M | |
Cash And Short Term Investments | 714.6M | 237.4M | 237.0M | 217.5M | 200.0M | 169.4M | |
Common Stock Total Equity | 324.8M | 249.8M | 262.3M | 267.3M | 307.4M | 244.1M | |
Common Stock Shares Outstanding | 46.3M | 30.8M | 30.0M | 30.4M | 30.4M | 36.4M | |
Liabilities And Stockholders Equity | 816.9M | 353.7M | 275.2M | 246.1M | 226.6M | 209.4M | |
Non Current Liabilities Total | 1.1M | 1.1M | 2.3M | 1.6M | 1.7M | 870.2K | |
Other Current Assets | 1.7M | 84.4M | 934K | 601K | 760K | 722K | |
Total Liab | 61.2M | 5.1M | 5.8M | 5.7M | 7.8M | 10.2M | |
Property Plant And Equipment Gross | 25.2M | 27.3M | 44.0M | 26.3M | 43.1M | 25.8M | |
Total Current Assets | 716.3M | 325.9M | 246.9M | 219.8M | 201.7M | 179.8M | |
Accumulated Other Comprehensive Income | (255K) | (106K) | 1.3M | 2.0M | 826K | 0.0 | |
Common Stock | 324.8M | 249.8M | 262.3M | 267.3M | 271.2M | 248.6M | |
Property Plant Equipment | 25.2M | 27.3M | 28.3M | 26.3M | 30.2M | 20.6M | |
Net Tangible Assets | 755.6M | 348.6M | 269.4M | 240.4M | 276.5M | 236.7M | |
Other Stockholder Equity | (255K) | (106K) | 1.3M | 2.0M | 826K | 0.0 | |
Other Liab | 1.1M | 1.1M | 2.3M | 1.6M | 1.9M | 2.0M | |
Retained Earnings Total Equity | 430.9M | 97.6M | 5.2M | (27.7M) | (31.9M) | (33.5M) | |
Non Currrent Assets Other | 27.3M | 75M | (1.1M) | (1.7M) | (1.5M) | (1.4M) | |
Net Invested Capital | 755.6M | 348.6M | 269.4M | 240.4M | 218.8M | 304.0M | |
Net Working Capital | 656.1M | 321.9M | 243.4M | 215.8M | 195.6M | 263.6M | |
Capital Stock | 324.8M | 249.8M | 262.3M | 267.3M | 271.2M | 220.6M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.